[go: up one dir, main page]

WO1993017046A1 - Nouvelle substance semblable a la lectine - Google Patents

Nouvelle substance semblable a la lectine Download PDF

Info

Publication number
WO1993017046A1
WO1993017046A1 PCT/JP1993/000216 JP9300216W WO9317046A1 WO 1993017046 A1 WO1993017046 A1 WO 1993017046A1 JP 9300216 W JP9300216 W JP 9300216W WO 9317046 A1 WO9317046 A1 WO 9317046A1
Authority
WO
WIPO (PCT)
Prior art keywords
cells
nue
fraction
kda
substance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP1993/000216
Other languages
English (en)
Japanese (ja)
Inventor
Jeman Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to JP51469693A priority Critical patent/JP3420582B2/ja
Publication of WO1993017046A1 publication Critical patent/WO1993017046A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C07K14/43586—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from silkworms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention relates to a novel method having cell aggregation activity, specific binding to immunoglobulin G (IgG), macrophage phagocytic activation, antiviral activity, etc., extracted from silkworm feces.
  • the present invention relates to a lectin-like substance and a pharmaceutical composition containing the lectin-like substance as an active ingredient.
  • Lectins are sugar-binding proteins that recognize and bind to specific sugar chain structures.
  • H. Stillraark first discovered lectin as a protein that aggregates red blood cells in castor seeds.
  • Lectin also called hemagglutinin or hemagglutinin, is known to be present not only in plants but also in influenza virus surface antigens and animal liver.
  • the main physiological actions of lectins are: 1) Blood cells specifically agglutinate red blood cells, 2) Specific agglutination of only certain types of cancer cells, 3) Promote lymphocyte division (mitogenic activity), 4) Toxicity to cells ⁇ ⁇ ⁇ ⁇ Specific uptake of waste proteins in the liver and the like is known.
  • lectins were initially used only as blood group search reagents by utilizing their ability to bind to sugar chains that determine the blood group present on the membrane surface of erythrocytes.
  • Some lectins, such as lectins have been found to cause various immunological phenomena, such as the blastogenesis of quiescent lymphocytes and the induction of differentiation into proliferating cells.
  • it has come to be used as a stimulator of the production of a physiologically active substance in an immune response.
  • lectin showed strong cohesiveness to malignant cells.Based on the fact that lectin binds to specific sugar chains present on the surface of malignant cells, lectin was used with labeled lectin. It is also used for diagnosis to detect cancer cells.
  • lectins especially lectins derived from animal body fluids and tissues, or lectin-like substances having activities similar to them, are involved in the initiation of animal development, differentiation, nervous system, immune system, New research and applications are expected to play various important roles, such as reactions and protein metabolism.
  • an object of the present invention is to provide a novel lectin-like substance.
  • the present inventors have focused on silkworm dung, which has been used as a folk medicine in Korea since ancient times, and added this silkworm dung extract to muscle differentiation cells (QM-RSV cells) to solve the above problems. They found that the cells that had adhered to the culture dish were detached and aggregated. The present inventors have succeeded in purifying this active substance singly, clarified its biochemical characteristics (molecular weight, isoelectric point, thermal stability, etc.), and agglutinated cells caused by the active substance. In addition to investigating in detail, the present inventors have found that it has specific binding to immunoglobulin G (IgG), activation of macrophage phagocytosis, and antiviral activity, and completed the present invention. Was.
  • IgG immunoglobulin G
  • Lectins are sugar-binding proteins that have a cell-aggregating effect, precipitate polysaccharides and complex saccharides, and their binding properties are blocked by monosaccharides and oligosaccharides.
  • the active substance purified according to the present invention binds to cell membrane sugar chains or proteins like lectin and has the action of aggregating cells, but the main sugar does not inhibit its activity .
  • the active substance in the present invention is a novel lectin-like substance that is considered to be different from known lectins, and was named NUE.
  • the NU E of the present invention relates to a novel lectin-like substance having the following biochemical characteristics.
  • the isoelectric point is pH 4.8.
  • IgG immunoglobulin G
  • ⁇ Activates the phagocytic activity of macrophages.
  • the NUE of the present invention can be isolated, for example, from a water-soluble substance extracted from silkworm feces.
  • the NUE of the present invention is obtained by extracting silkworm feces with a 10-fold volume of PBS (-), removing the insoluble substance from the extract by filtration and centrifugation, and removing the supernatant obtained by NUE physical chemistry. It can be obtained by purifying by a combination of various separation means utilizing the characteristic properties.
  • a method combining salting out method, dialysis method, isoelectric point precipitation, and reverse phase HPLC can be exemplified. Specifically, ammonium sulfate was added to the above extraction supernatant to a concentration of 50%, and the obtained precipitate was dialyzed against PBS (-), and further subjected to isoelectric point precipitation at pH 3.5. The precipitate can be prepared by subjecting it to reverse phase HP LC or the like.
  • NUE was determined to be a glycoprotein by testing whether or not it was recognized by lectin blotting.
  • reagents used in the lectin blot method concanavalin VIII, peanut lectin, wheat embryo lectin-peroxidase are used.
  • the NUE of the present invention shows a single broad band at about 60 kDa on SDS-PAGE under non-reducing conditions, and about 5 kDa and about 17 kDa on SDS-PAGE under reducing conditions. Move as a sensitive band in the book.
  • examples of cells that cause aggregation by NUE include Ehrlich ascites cancer cells, QM-RSV cells, and He1a cells.
  • myoblasts Quail myoblast, QM
  • QM Rous sacoma virus
  • RSV Rous sacoma virus
  • QM-RSV cells At the permissive RSV temperature of 35.5, QM-RSV cells continue to grow as undifferentiated myoblasts, but at 41 ° C they begin to differentiate and form multinucleated myotubes. In other words, it is a cell whose muscle differentiation process can be controlled by temperature.
  • the binding characteristic between NUE and immunoglobulin G can be assayed by the stantam blot method using egos IgG.
  • the NUE of the present invention binds to all of IgG Fab, Fc, H chain and L chain. Since no sugar chain exists only in the Fc portion of IgG, NUE is considered to recognize sites other than sugar chains.
  • NUE even in IgG that has been reduced to a higher-order structure by being reduced, it binds to ⁇ , suggesting that the site recognized by NUE is the primary structure of IgG.
  • the binding of NUE to IgG is not seen by IgG trypsin ⁇ S. Therefore, the site recognized by ⁇ is thought to contain an amino acid sequence that is cleaved by trypsin.
  • the NUE of the present invention has a possibility of being useful for analyzing a phenomenon in which cells adhere and aggregate to each other in a growth process in which cells proliferate and differentiate to form a complex tissue.
  • it can be applied to various clinical diagnoses, such as cancer diagnosis, by utilizing the binding properties between the substance and tissues (particularly, malignant cells).
  • the substance since the substance has specific binding properties to immunoglobulin G, it is expected to be used as a research reagent in the field of immunology.
  • the substance activates the phagocytic activity of macrophages, thereby preventing infection by pathogens (viruses and bacteria) or improving immunity against them.
  • the substance has been found to have antiviral activity, especially anti-Sendai virus (HVJ), anti-HIV activity, anti-Hashika virus activity, and anti-herpes virus activity. It has strong antiviral activity against envelope viruses including influenza virus and hepatitis B virus. Therefore, the NUE of the present invention is effective as an immunostimulant because of its phagocytic activity of the macula phage, and as an antiviral agent because of its antiviral effect, and has both effects. In other words, it is effective as an agent for preventing and treating infectious diseases.
  • HVJ anti-Sendai virus
  • Hashika virus activity anti-Hashika virus activity
  • anti-herpes virus activity It has strong antiviral activity against envelope viruses including influenza virus and hepatitis B virus. Therefore, the NUE of the present invention is effective as an immunostimulant because of its phagocytic activity of the macula phage, and as an antiviral agent because of its antiviral effect, and has
  • the prophylactic / therapeutic agent for infectious diseases comprising NUE as an active ingredient in the present invention is administered orally or by injection after depolymerization.
  • the composition is administered in an appropriate form according to each administration route, for example, formulated as an oral preparation or an injection.
  • Oral formulations eg, tablets, capsules
  • injectable formulations are each manufactured by conventional methods.
  • Each formulation usually contains a pharmaceutically acceptable carrier or additive depending on the dosage form.
  • an ointment is typically used as a dosage form, and the preparation may be prepared by a conventional method using a conventional carrier such as an excipient, an emulsifier, a stabilizer, if necessary. Can be prepared.
  • the content of the active ingredient NUE in the preventive / therapeutic agent for infectious disease is not particularly limited because it can be appropriately changed depending on the administration method, dosage form, applicable disease and the like.
  • the dosage of the infectious disease prophylactic / therapeutic agent varies depending on the applicable disease, the degree of the disease, the patient's annual meeting, etc.
  • 50-50 mg / m1 is usually applied to the affected area several times a day.
  • FIG. 1 shows the elution pattern of the silkworm dung extract purified by reverse phase HPLC.
  • Fig. 2 shows the detachment state (biological cell morphology) of myoblasts (QM-RSV cells) from the culture vessel wall by the "NUE" fraction.
  • FIG. 3 shows the SDS-polyacrylamide electrophoresis pattern of each purified fraction of the silkworm feces extract under reducing and non-reducing conditions.
  • FIG. 4 shows a lectin blot image (electrophoresis pattern) using a “NUE” fraction of concanavalin A.
  • FIG. 5 shows the absorbance curve for the "NUE" fraction.
  • FIG. 6 shows the aggregation state (biological cell morphology) of myoblasts (QM-RSV cells) in the culture at 35.5 ° C. with the addition of “NUE” fraction.
  • FIG. 7 shows the aggregation state (biological cell morphology) of myoblasts (QM-RSV cells) in the culture at 41 ° C. with the addition of the “NUE” fraction.
  • Figure 8 shows the adherence of the myoblasts (QM-RSV cells) untreated, pre-treated, and removed after pre-treatment to the culture vessel wall (organism of the biological cells) at 35.5 ° C. .
  • Fig. 9 shows the state of adhesion (biological cell morphology) of myoblasts (QM-RSV cells) untreated, pretreated, and removed after pretreatment to the culture vessel wall at 41 ° C.
  • FIG. 10 shows the degree of aggregation by the “NUE” fraction in the cells in suspension.
  • FIG. 11 shows a western blot image (electrophoretic pattern) using a “NUE” fraction of egret IgG.
  • Silkworm dung was obtained in a dry state from the Nagano Prefectural Silkworm Experimental Station.
  • the freeze-dried silkworm feces extract was dissolved in distilled water to a concentration of 10 mg / ml, and the pH was lowered to pH 3.5 with 0.5 M acetic acid. The mixture was left at 4 for 1 hour, and centrifuged at 10 4 Xg for 15 minutes. The pH was raised to 7 with 1M NaOH, and the precipitate was dissolved in an appropriate amount of PBS (-).
  • Reversed phase HPLC was performed using a U6K pump, a Waters 600B system cotroller, a Waters 484 tunable absorbance detector, a Waters 741 data module (above Waters), and a model 201 fraction collector (Gilson).
  • Column The procedure was carried out at room temperature using a Protein C 4 column (Vydac 10 hidden x 25 cm, particle size 5 mm,? L size 300 A).
  • Eluate A contains 0.1% trifluoroacetic acid- Distilled water and eluent B were eluted with acetonitrile containing 0.1% trifluoroacetic acid at a flow rate of 3 ml / min.
  • the pectoral muscle was removed from the Pezula embryo on day 10, and the cells were suspended in 0.25% trypsin (Difco Labolatories), and then spread in a growth medium so as to form 1 ⁇ 10 6 cells / lOOram glass culture dish. Trypsin is dissolved in PBS (-), and the growth medium is 20% fetal bovine serum (FBS), 2mM glutamate (Nissui Pharmaceutical Co., Ltd.), 0.2% sodium bicarbonate, 100 units / DMEM (Dulbecoo's modification of Eagle's medium, Flow Laboratories) containing ml penicillin G potassium and 100 g / ml streptomycin sulfate was used.
  • trypsin is dissolved in PBS (-)
  • FBS fetal bovine serum
  • 2mM glutamate Nasui Pharmaceutical Co., Ltd.
  • sodium bicarbonate 100 units / DMEM (Dulbecoo's modification of Eagle's medium, Flow Laborator
  • the culture dish was cultured at 37 for 1.5 hours at 37 with gentle shaking every 10 minutes to select for myoblasts and fibroblasts. This operation was performed once more in order to perform the screening more sufficiently.
  • the cells that had not adhered to the culture dish at this time were used as myoblasts and spread on a 60-mm plastic culture dish (CORNING) so as to obtain 5.9 ⁇ 10 5 cells / 3 ml growth medium.
  • the plastic culture dishes were pretreated with collagen (Type-IP, Nitta Gelatin Co., Ltd.). This is the temperature-sensitive Rous sarcoma virus
  • QM-RSV cells were seeded into collagen-treated 35 thigh plastic culture dishes to give 2 x 10 5 Z2 ml growth media. After culturing at 35.5 ° C for 24 hours, a differentiation medium containing 200 zg / ml silkworm feces extract (5% FBS, 2 mM glumin, 0.2% sodium bicarbonate, 100 units / ml potassium penicillin G, 100 ug / ml streptomycin sulfate was replaced with DMEM medium, and the cells were cultured at 35.5 ° C and observed at regular intervals. The time required for the cells adhered to the culture dish to separate and to agglomerate is assured at 6 hours after the addition of the silkworm feces extract. 2) o
  • SDS-PAGE was performed according to the method of Lae Thighli et al. [Laemmli, U.K., Cleavage of Structure Proteins during the Assembly of the Head of Bacteriophage T4, Nature, 227, 680-685 (1970)]. All separation gels were prepared by adding 12.5% acrylamide (manufactured by Wako Pure Chemical Industries, Ltd.). After electrophoresis of the sample at a constant current of 20 mA, the sample was stained with Coomassie Brilliant Blue R250 (fluka Chemie AG).
  • the lectin-plot method was performed as follows. After SDS-PAGE, the protein band separated on the gel was passed for 2 hours at a constant current of 50 mA, and transferred to Nitrocell mouth paper (Bio Rad Laboratories). The nitrocellulose paper was washed five minutes twice with distilled water, soaked for 1 hour at 80 ° C in 25 ⁇ H 2 S0 4. Then, wash twice with distilled water twice for 5 minutes each with T buffer (0.15 NaCl-0.053 ⁇ 4 Tween20-10mM Tris ⁇ HC1, pH 7.4) for 5 minutes each. Then, concanapalin A-peroxidase reagent ( (Honen Oil Co., Ltd.) at 4 ° C for 1 hour.
  • T buffer (0.15 NaCl-0.053 ⁇ 4 Tween20-10mM Tris ⁇ HC1, pH 7.4
  • Concanavalin A-peroxidase reagent was diluted 100-fold with T buffer, and lmM CaCl 2 .nCh.gCh was added. After the reaction, the nitrocell mouth paper was washed four times with T buffer for 15 minutes and twice for 5 minutes each with 15 mM phosphate buffer pH 6.7, and 3 mg / ml 4-chloro-1-naphthol (Bio Rad Laboratories) ) and 0.02% H 2 0 2 was added and allowed to develop. 4 one chloro 1 one naphthol was added to methanol, H 2 0 2 was diluted with 15mM phosphate buffer. The color development was stopped by washing with distilled water.
  • Figure 4 shows the results of a plot of lectin using this peroxidase-conjugated concanapalin reagent. Shown in Under non-reducing conditions, that is, sugar binding to the 60 kDa protein was confirmed (Fig. 4, lane 2). Similarly, the 60 kDa protein was also recognized by the peanut lectin and wheat beoxidoxidase reagents.
  • QM-RSV cells were seeded on a 35 mm culture dish so as to give 2 ⁇ 10 5 cells / 2 ml growth medium, and cultured at 35.5 ° C. for 24 hours.
  • the medium was replaced with a differentiation medium containing 200 ug / nd or 400 / g / ml silkworm dung extract, and cultured at 35.5 and 41 ° C, respectively.
  • QM-RSV cells were collected with 0.02% EDTA / PBS (-), and adjusted to 2 x 10 5 cells / ml in a differentiation medium with or without 400 g / ral silkworm feces extract. After standing on ice for 15 minutes, the cells were diluted 2-fold with the differentiation medium, and cultured in a 35 ⁇ culture dish at 21111: 35.5 and 41. To remove the "NUE" fraction added to the cells from the cells, dilute twice with the differentiation medium, centrifuge at lOOOOrpm for 5 minutes to remove the supernatant, and remove the remaining cells into 2 x 10 5 cells / 2ml differentiation medium was spread on a 35 mm culture dish as described above, and cultured in the same manner.
  • QM-RSV cells were spread on a 100-fold culture dish so as to have 1.6 ⁇ 10 6 cells / 5 ml of growth medium, and cultured at 35.5 ° C. for 24 hours.
  • the QM-RSV cells were collected with 0.02% EDTA and suspended in PBS (-) at a concentration of 5 ⁇ 10 6 cells / ml.
  • PBS PBS
  • the "NUE” fraction exhibits cell aggregation activity by binding to the cell surface.
  • each cell was examined for aggregation by the "NUE" fraction.
  • ⁇ 10101 ⁇ cells were seeded into a 100 ⁇ glass culture dish so as to be 3 10 6 / 5ml 103 ⁇ 4 CS-MEM and cultured at 37 ° C for 24 hours.
  • the cells were collected with a 1: 1 mixture of 0.25% tribcine (Difco Laboratories) and 0.02% EDTA, and aggregation was observed.
  • Tribcine and EDTA were dissolved in PBS (1).
  • He1a cells also showed agglutinating activity in the same manner as MDCK cells.
  • Chicken erythrocytes were collected from white leghorn wing vein, washed with PBS (1), and examined for agglutinating activity in the same manner.
  • Ehrlich ascites carcinoma cells were grown in the peritoneal cavity of ddy male mice, and after washing with PBS (-), showed similar agglutinating activity.
  • QM-RSV cells were collected with 0.25% trypsin and aggregated similarly. The results are shown in Table 1. All cells aggregated in a "NUE" fraction. In particular, Ehrlich ascites carcinoma cells aggregated strongly, but other cells did not show as strong agglutination as QM-R SV cells.
  • the Western plot method was performed as follows. After SDS-PAGE, the proteins separated on the gel were energized at 50 mA for 2 hours and transferred to nitrocellulose paper (Bio Rad Lab-oratories). This nitrocellulose paper was placed in TBS (Tis buffered saline; 20m Tris-HC1 pH 7.4-0.5M NaCl) for 10 minutes with a blocking solution (3% gelatin).
  • IgG was used. Egret IgG was purified from serum obtained from Japanese White Egret using Ampure (registered trademark) PA kit. After the reaction with the primary antibody, the cells were washed twice with T'TBS for 5 minutes each, and then reacted with the secondary antibody.
  • the secondary antibody used was a horseradish peroxidase-conjugated anti-pawn heron IgG goat antibody (Bio Rad Laboratories) diluted 1,500-fold with an antibody solution (1% gelatin / T.TBS). After washing twice with T ⁇ TBS twice for 5 minutes and twice with TBS for 5 minutes each, SmgZml 1-chloro-41-naphthol and 0.02% hydrogen peroxide solution were added to develop color. 1-chloro-41-naphthol was dissolved in methanol and aqueous hydrogen peroxide was diluted with TBS. Color development was stopped by washing with H 2 0. The results are shown in FIG.
  • Proteose peptone was administered intraperitoneally to ddy male mice, and macrophages were allowed to migrate into the intraperitoneal cavity. A few days after administration, ascites was collected using MEM (Minimum essential medium) containing heparin and 10% calf serum (CS), and macrophages were collected. After washing the macrophages with the same culture solution, they were spread at a concentration of 2 ⁇ 10 6 2 ml 10% CS-MEM in a 35 mm glass culture dish containing a forcepour.
  • MEM Minimum essential medium
  • CS calf serum
  • the culture medium was replaced with 2 ml of 10% CS-MEM containing 200 igl of the "NUE” fraction, and "NUE” fraciion was allowed to act on the cells at 37 for 24 hours.
  • the culture medium was exchanged for 10% CS-MEM containing 2 ⁇ 10 6 Zml of latex beads, and the beads were incorporated into the cells for 20 minutes at 37. After fixing the cells with glutaraldehyde, the number of incorporated beads was determined. Count the number of beads incorporated into 100 macrophages The results were expressed as the number of beads taken up per cell.
  • the control yielded 3.16 ⁇ 1.51 cells / macrophage, while the “NUE” fraction produced 11.02 ⁇ 2.64 cells / macrophage, which was a three-fold or more difference. Therefore, it was shown that the macrophage phagocytic activity was activated by the "NUE" fraction.
  • HVJ 1 HAu (3 ⁇ 10 7 viruses Zm 1) was allowed to act on the “NUE” fraction at a concentration of 400 ngl for 3 minutes, and then diluted 3-fold with PBS ( ⁇ ). After serially diluting this solution 10 times, each diluted solution was used to infect 100 embryos of 5 embryonated chicken eggs on day 10. On the third day after the infection, urine fluid was collected, and the agglutination value of chicken erythrocytes was examined for each to determine the presence or absence of virus infection. When all the eggs of the control (without “NUE” fraction) were infected, the infection was established, but when the "NUE" fraction was applied, no virus infection was observed, and the "NUE" fraction was infected with HVJ. Was suggested to inhibit
  • control is 1 ⁇ 10 6 ⁇ 45 TClD 5 ./ml If contrast, allowed to act "NUE” fraction, infectivity 1 ⁇ 10 5 ⁇ 45 is inhibited until the TCID 50 / ml (1/10 times that of the control), "NUE” the fraction anti-HIV It was shown to work.
  • the novel lectin-like substance of the present invention is useful not only for analyzing cell aggregation mechanisms important in cell biology, but also as a research reagent in the field of immunology by utilizing its specific binding to IgG. The use of is expected. Furthermore, since it has macrophage phagocytic activating activity and antiviral activity, it aims to prevent, treat, reduce symptoms, and prevent or suppress symptom exacerbation against various infections including virus infection. It is effective as an agent for preventing and treating infectious diseases.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Insects & Arthropods (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Nouvelle substance semblable à la lectine et caractérisée en ce que: (1) elle provient des excréments des vers à soie; (2) elle présente un poids moléculaire évalué à 60 kDa selon SDS-PAGE dans des conditions non réductrices, et à 50 kDa et 17 kDa dans des conditions réductrices; (3) elle présente un point isoélectrique de pH 4,8; (4) elle est une glycoprotéine; (5) elle présente une activité de cyto-agglutinine; et (6) elle se combine de manière spécifique à l'immunoglobuline G. Cette substance sert à analyser les phénomènes d'adhésion et d'agglutination cellulaires au cours de l'évolution des cellules, dans laquelle les cellules croissent et se différencient de manière à former des tissus complexes. En outre, il peut avantageusement servir de réactif diagnostique clinique, notamment pour le cancer, et de réactif destiné à la recherche dans le domaine immunologique, grâce à sa capacité de combinaison aux cellules malignes ou à l'immunoglobuline. Par ailleurs, il peut efficacement servir à la prophylaxie, au traitement et à l'atténuation de diverses maladies infectieuses caractérisées par une infection virale, ainsi qu'à l'inhibition ou à la suppression de toute aggravation de ces maladies, puisqu'il a l'effet d'activer la phagocytose des macrophages, ainsi qu'une activité antivirale.
PCT/JP1993/000216 1992-02-25 1993-02-22 Nouvelle substance semblable a la lectine Ceased WO1993017046A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP51469693A JP3420582B2 (ja) 1992-02-25 1993-02-22 新規レクチン様物質

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP7513592 1992-02-25
JP4/75135 1992-02-25

Publications (1)

Publication Number Publication Date
WO1993017046A1 true WO1993017046A1 (fr) 1993-09-02

Family

ID=13567451

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP1993/000216 Ceased WO1993017046A1 (fr) 1992-02-25 1993-02-22 Nouvelle substance semblable a la lectine

Country Status (2)

Country Link
JP (1) JP3420582B2 (fr)
WO (1) WO1993017046A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101864425A (zh) * 2010-05-17 2010-10-20 山东大学 家蚕c-型凝集素重组表达方法及应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104483422B (zh) * 2014-12-24 2017-02-22 湖北省农业科学院经济作物研究所 一种家蚕血液中乐果的提取方法及过滤装置

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6377900A (ja) * 1986-09-18 1988-04-08 Sanwa Kagaku Kenkyusho Co Ltd ヤママユガ由来のレクチン様物質及びその分離精製法並びにその用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6377900A (ja) * 1986-09-18 1988-04-08 Sanwa Kagaku Kenkyusho Co Ltd ヤママユガ由来のレクチン様物質及びその分離精製法並びにその用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, Vol. 106, No. 21, 25 May 1987, (Columbus, Ohio, USA), S. LI et al., "Isolation and Characterization of Lectin in Hemolymph from Pupae of the Chinese Oak Silkworm Antheraea Pernyi", Abstract No. 174437V; & KUNCHONG XUEBAO, 30(1), 1-7. *
CHEMICAL ABSTRACTS, Vol. 99, No. 19, 7 November 1983, (Columbus, Ohio, USA), Y. KATO et al., "Changes in the Hemagglutinating Activity of Glycoprotein in Hemolymph of the Silkworm, Bombyx Mori", Abstract No. 156625n; & NIPPON SANSHIGAKU ZASSHI, 52(3), 247-8. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101864425A (zh) * 2010-05-17 2010-10-20 山东大学 家蚕c-型凝集素重组表达方法及应用

Also Published As

Publication number Publication date
JP3420582B2 (ja) 2003-06-23

Similar Documents

Publication Publication Date Title
EP0584558B1 (fr) Composition pour supprimer l'infection et la croissance du virus de l'immunodéficience humaine en utilisant une protéine fixant le fer
JPH07503851A (ja) 改良インターフェロン及びヒトの末梢血液白血球からのその製造方法
Gondim et al. Potent antiviral activity of carbohydrate-specific algal and leguminous lectins from the Brazilian biodiversity
CN103476418A (zh) 用于治疗由流感病毒引起的疾病的硫酸阿拉伯半乳聚糖、芹菜糖半乳糖醛酸聚糖和硫酸杂聚糖
JPS63316730A (ja) 抗ウイルス剤
FI72143C (fi) Foerfarande foer framstaellning av maenniskointerferon.
Roelcke et al. I-, MN-and Pr (1)/Pr (2)-Activity of Human Erythrocyte Glycoprotein Fractions Obtained by Ficin Treatment
WO1991006311A1 (fr) Matiere antivirale
US5712245A (en) Receptor of the minor human rhinovirus receptor group
US5603932A (en) Receptor of the minor human rhinovirus receptor group
IE881110L (en) Receptor of the small rhinovirus receptor group
WO1993017046A1 (fr) Nouvelle substance semblable a la lectine
CA1339111C (fr) Agent antiviral
EP1046397A2 (fr) Nouvelle substance bioactivatrice
Gowrishankar et al. Leucocyte migration inhibition with human heart valve glycoproteins and group A streptococcal ribonucleic acid proteins in rheumatic heart disease and post-streptococcal glomerulonephritis
EP0158317A2 (fr) Méthode pour la préparation d'un composé biologique
JP2005502597A (ja) 韓国産エゾウコギ抽出物、これに由来する抽出蛋白質及び粗蛋白多糖類、そしてこれを有効成分とする免疫調節用組成物及びその用途
RU2195308C1 (ru) Способ получения вещества, обладающего иммуностимулирующей, противовирусной и антибактериальной активностью, вещество, полученое этим способом, и фармацевтическая композиция на его основе
EP0048283A1 (fr) Substance inhibant les virus et procede de preparation de celle-ce
JPWO1993017046A1 (ja) 新規レクチン様物質
JP4014330B2 (ja) ウイルス感染防御剤
US9616091B2 (en) Methods and compositions containing at least 30% IgG and 10% or less by weight IgA for reducing lung inflammation in an animal
EP0100366A1 (fr) Agent de traitement d'allergies de maladies du complexe immunitaire et de tumeurs
JP4306828B2 (ja) 病原性細菌感染防御剤
CN101274097B (zh) 喷雾流行性感冒疫苗组合物及其制备方法

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA JP KR US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 1993904333

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1993904333

Country of ref document: EP

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA